<DOC>
	<DOCNO>NCT00545545</DOCNO>
	<brief_summary>Phase 1b , safety , pharmacokinetic , efficacy , multicenter , dose-escalating Study Imprime PGG™ Injection dose combination Cetuximab concomitant irinotecan therapy . Enrolled patient confirm diagnosis recurrent progressive colorectal carcinoma follow treatment 5-fluorouracil-containing regimen .</brief_summary>
	<brief_title>Safety/Efficacy Study Imprime PGG With Cetuximab Patients With Recurrent/Progressive Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Is ages 18 75 year old , inclusive ; 2 . Has recurrent progressive carcinoma colon rectum document histological confirmation primary carcinoma ; 3 . Has measurable disease , define least one tumor fulfill criterion target lesion accord RECIST ; 4 . Has previously receive treatment 5FU , alone combination antitumor medication ( except exclusion # 1 ) ; Prior treatment capecitabine ( Xeloda® ) consider fulfill requirement prior treatment 5FU ; 5 . Has Karnofsky Score ≥ 70 ; 6 . Has life expectancy &gt; 3 month ; 7 . Has adequate bone marrow reserve evidence : 1 . ANC ≥ 1,500/μL 2 . PLT ≥ 100,000/μL 3 . HGB ≥ 9 g/dl ; 8 . Has adequate renal function evidence serum creatinine ≤ 1.5X upper limit normal ( ULN ) reference lab ; 9 . Has adequate hepatic function evidence : 1 . Serum total bilirubin ≤ 1.0 mg/dL 2 . AST ≤ 3X ULN reference lab ( ≤ 5X ULN patient know hepatic metastasis ) 3 . ALT ≤ 3X ULN reference lab ( ≤ 5X ULN patient know hepatic metastasis ) ; 10 . Has discontinue CYP3A4 enzymeinducing anticonvulsant ( phenytoin , phenobarbital carbamazepine ) antimicrobial ( refampin rifabutin ) , St. John 's Wort , ketoconasole least two week prior Day 1 11 . Has recover effect prior surgery , radiotherapy , chemotherapy ; 12 . Has read , understood sign informed consent form ( ICF ) approve Independent Review Board/Ethics Committee ( IRB/EC ) ; 13 . If woman childbearing potential fertile man ( partner ) , must agree use effective form contraception study 120 day follow last dose study medication ( effective form contraception hormonal contraceptive doublebarrier method ) . 1 . Has previously receive treatment cetuximab irinotecan ; 2 . Has know hypersensitivity cetuximab , murine protein , component cetuximab ; 3 . Has hereditary fructose intolerance ; 4 . Has know hypersensitivity baker 's yeast , active yeast infection ; 5 . Has previous exposure Betafectin® Imprime PGG ; 6 . Has receive previous radiation therapy &gt; 30 % active bone marrow ; 7 . Has fever &gt; 38.5º C within 3 day prior initial dosing ; 8 . Has know suspected central nervous system ( CNS ) metastases ; 9 . Had second malignancy within previous 5 year , except basal cell carcinoma , cervical intraepithelial neoplasia curativelytreated prostate cancer PSA &lt; 2.0 ng/mL ; 10 . Has know HIV/AIDS , Hepatitis B , Hepatitis C , connective tissue autoimmune disease , clinical diagnosis , ongoing intercurrent illness investigator 's opinion would prevent participation ; 11 . If female , pregnant breastfeeding ; 12 . Is receive concurrent investigational therapy receive investigational therapy within period 30 day prior first schedule day dose ( investigational therapy define treatment currently regulatoryauthorityapproved indication ) ; 13 . Has previously receive organ progenitor/stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Colorectal</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Progressive</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>5-Fluorouracil</keyword>
</DOC>